Metabolite identification studies on amiodarone in in vitro (rat liver microsomes, rat and human liver S9 fractions) and in vivo (rat feces, urine, plasma) matrices by using liquid chromatography with high-resolution mass spectrometry and multiple-stage mass spectrometry: Characterization of the diquinone metabolite supposedly responsible for the drug's hepatotoxicity

Rapid Communications in Mass Spectrometry

Volumn 28, Issue 4, 2014, Pages 311-331

  Varkhede, Ninad Ramesh ^a   Jhajra, Shalu ^a   Ahire, Deepak Suresh ^a   Singh, Saranjit ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMOLECULES; BODY FLUIDS; DRUG PRODUCTS; FREE RADICALS; KETONES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; RATS; TOXICITY;

AMIODARONE; HEPATOTOXICITY; HUMAN LIVER; IN-VITRO; IN-VIVO; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; METABOLITE IDENTIFICATION; PLASMA MATRIX; RAT LIVER MICROSOMES; RAT LIVERS;

METABOLITES;

AMIODARONE; DRUG DERIVATIVE; QUINONE DERIVATIVE;

ANIMAL; ARTICLE; BLOOD; COMPUTER SIMULATION; FECES; HUMAN; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; RAT; TOXICITY TESTING; URINE; WISTAR RAT;

AMIODARONE; ANIMALS; CHROMATOGRAPHY, LIQUID; COMPUTER SIMULATION; FECES; HUMANS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; QUINONES; RATS; RATS, WISTAR; TOXICITY TESTS;

EID: 84891782635     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6787     Document Type: Article

References (47)

1. S. R. Punnam, S. K. Goyal, V. P. K. Kotaru, A. R. Pachika, G. S. Abela, R. K. Thakur,. Amiodarone-A 'broad spectrum' antiarrhythmic drug. Cardiovasc. Haematol. Disord. (Formerly Curr. Drug Targets: Cardiovasc. & Haematol. Disord.) 2010, 10, 73.
2. S. Pourbaix, Y. Berger, J. P. Desager, M. Pacco, C. Harvengt,. Absolute bioavailability of amiodarone in normal subjects. Clin. Pharm. Ther. 1985, 37, 118.
3. P. Deng, T. You, X. Chen, T. Yuan, H. Huang, D. Zhong,. Identification of amiodarone metabolites in human bile by ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry. Drug Metab. Dispos. 2011, 39, 1058.
4. H. R. Ha, L. Bigler, B. Wendt, M. Maggiorini, F. Follath,. Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients. Eur. J. Pharm. Sci. 2005, 24, 271.
5. J. M. Trivier, C. Libersa, C. Belloc, M. Lhermitte,. Amiodarone N-deethylation in human liver microsomes: Involvement of cytochrome P450 3A enzymes (first report). Life Sci. 1993, 52, PL91.
6. S. W. Myung, Y. J. Chang, H. K. Min, D. H. Kim, M. Kim, T. K. Kang, E. A. Yoo, Y. T. Sohn, Y. H. Yim,. Characterization of amiodarone metabolites and impurities using liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2000, 14, 2046.
7. R. A. Young, H. M. Mehendale,. In vitro metabolism of amiodarone by rabbit and rat liver and small intestine. Drug Metab. Dispos. 1986, 14, 423.
8. H. R. Ha, L. Bigler, M. Binder, P. Kozlik, B. Stieger, M. Hesse, H. R. Altorfer, F. Follath,. Metabolism of amiodarone (part I): Identification of a new hydroxylated metabolite of amiodarone. Drug Metab. Dispos. 2001, 29, 152.
9. G. Fabre, B. Julian, B. Saint-Aubert, H. Joyeux, Y. Berger,. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab. Dispos. 1993, 21, 978.
10. H. R. Ha, P. Kozlik, B. Stieger, L. Bigler, F. Follath,. Metabolism of amiodarone (part II): High-performance liquid chromatographic assay for mono-N-desethylamiodarone hydroxylation in liver microsomes. J. Chromatogr. B 2001, 757, 309.
11. P. Kozlik, H. R. Ha, B. Stieger, L. Bigler, F. Follath,. Metabolism of amiodarone (part III): Identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone. Xenobiotica 2001, 31, 239.
12. A. Shayeganpour, A. O. S. El-Kadi, D. R. Brocks,. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: The contribution of cytochrome P450 3A isoforms. Drug Metab. Dispos. 2006, 34, 43.
13. S. R. Puli, M. A. Fraley, V. Puli, A. B. Kuperman, M. A. Alpert,. Hepatic cirrhosis caused by low-dose oral amiodarone therapy. Am. J. Med. Sci. 2005, 330, 257.
14. D. C. Evans, A. P. Watt, D. A. Nicoll-Griffith, T. A. Baillie,. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004, 17, 3.
15. N. Gassanov, E. Caglayan, E. Erdmann, F. Er,. Amiodarone-induced liver dysfunctions. Dtsch. Med. Wochenschr. 2010, 135, 1372.
16. M. Atiq, J. C. Davis, L. W. Lamps, S. S. Beland, J. E. Rose,. Amiodarone induced liver cirrhosis. Report of two cases. J. Gastrointestin. Liver Dis. 2009, 18, 233.
17. M. Lahbabi, N. Aqodad, A. Ibrahimi, M. Lahlou, H. Aqodad,. Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy. World J. Hepatol. 2012, 4, 196.
18. P. Kaufmann, M. Török, A. HÓnni, P. Roberts, R. Gasser, S. KrÓhenbühl,. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005, 41, 925.
19. M. Spaniol, R. Bracher, H. R. Ha, F. Follath, S. KrÓhenbühl,. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J. Hepatol. 2001, 35, 628.
20. A. I. Morales, J. D. Barata, M. Bruges, M. A. Arévalo, J. M. González de Buitrago, P. Palma, P. Branco, F. Pérez-Barriocanal. Acute renal toxic effect of amiodarone in rats. Pharmacol. Toxicol. 2003, 92, 39.
21. J. S. M. Sarma, H. Pei, K. Venkataraman,. Role of oxidative stress in amiodarone-induced toxicity. J. Cardiovasc. Pharmacol. Ther. 1997, 2, 53.
22. R. A. Zidan,. Effect of long-term administration of amiodarone on rat lung and the possible protective role of vitamin E: A histological and immunohistochemical study. Egyptian J. Histol. 2011, 34, 117.
23. R. G. Leeder, E. Rafeiro, J. F. Brien, C. C. Mandin, T. E. Massey,. Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. J. Biochem. Toxicol. 1996, 11, 147.
24. A. Vereckei, A. Blazovics, I. Gyorgy, E. Feher, M. Toth, G. Szenask, A. Zsinka, G. Foldiak, J. Feher,. The role of free radicals in the pathogenesis of amiodarone toxicity. J. Cardiovasc. Electr. 1993, 4, 161.
25. A. Zahno, K. Brecht, R. Morand, S. Maseneni, M. Török, P. W. Lindinger, S. KrÓhenbühl,. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem. Pharmacol. 2011, 81, 432.
26. G. Istvan, F. Gabor,. Free-radical induced redox reactions of drugs: A pulse radiolysis study. Magyar Kemiai Folyoirat 1992, 98, 361.
27. T. M. Polasek, D. J. Elliot, B. C. Lewis, J. O. Miners,. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J. Pharmacol. Exp. Ther. 2004, 311, 996.
28. R. S. Obach, R. L. Walsky, K. Venkatakrishnan,. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007, 35, 246.
29. N. Isoherranen, H. Hachad, C. K. Yeung, R. H. Levy,. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: Literature evaluation based on the metabolism and transport drug interaction database. Chem. Res. Toxicol. 2009, 22, 294.
30. M. H. H. Lee, G. G. Graham, K. M. Williams, R. O. Day,. A benefit-risk assessment of benzbromarone in the treatment of gout: Was its withdrawal from the market in the best interest of patients? Drug Safety 2008, 31, 643.
31. M. G. McDonald, A. E. Rettie,. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: Formation of glutathione adducts from a catechol intermediate. Chem. Res. Toxicol. 2007, 20, 1833.
32. US-FDA, Guidance for industry, Safety Testing of Drug Metabolites, Rockville, MD, USA, 2008.
33. Available: http://www.acdlabs.com/resources/freeware/.
34. B. Prasad, S. Singh,. In vitro and in vivo investigation of metabolic fate of rifampicin using an optimized sample preparation approach and modern tools of liquid chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 2009, 50, 475.
35. X. Bi, Z. Meng, H. Chen, X. Zhu, G. Dou,. In vivo and in vitro metabolism of lefucoxib in rats. J. Pharm. Biomed. Anal. 2008, 48, 134.
36. A. Shayeganpour, D. A. Hamdy, D. R. Brocks,. Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone. Biopharm. Drug Dispos. 2008, 29, 159.
37. n and LC-HR-MS. Eur. J. Pharm. Sci. 2010, 41, 173.
38. M. S. Chang, Q. Ji, J. Zhang, T. A. El-Shourbagy,. Historical review of sample preparation for chromatographic bioanalysis: Pros and cons. Drug Develop. Res. 2007, 68, 107.
39. B. Prasad, A. Garg, H. Takwani, S. Singh,. Metabolite identification by liquid chromatography-mass spectrometry. TrAC-Trend. Anal. Chem. 2011, 30, 360.
40. M. Zhu, L. Ma, D. Zhang, K. Ray, W. Zhao, W. G. Humphreys, G. Skiles, M. Sanders, H. Zhang,. Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab. Dispos. 2006, 34, 1722.
41. P. J. Arnold, R. Guserle, V. Luckow, R. Hemmer, H. Grote,. Liquid chromatography-mass spectrometry in metabolic research: I. Metabolites of benzbromarone in human plasma and urine. J. Chromatogr. A 1991, 554, 267.
42. K. Enslein, V. K. Gombar, B. W. Blake,. International commission for protection against environmental mutagens and carcinogens. Use of SAR in computer-assisted prediction of carcinogenicity and mutagenicity of chemicals by the TOPKAT program. Mutat. Res. 1994, 305, 47.
43. S. K. Lee, J. Lee, E. S. Lee, Y. Jahng, D. H. Kim, T. C. Jeong,. Characterization of in vitro metabolites of rutaecarpine in rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2004, 18, 1073.
44. S. Jhajra, N. Ramesh Varkhede, D. Suresh Ahire, B. Vidyasagar Naik, B. Prasad, J. Paliwal, S. Singh, A. V. Lyubimov,. Extrahepatic drug metabolizing enzyme and their significance, in Encyclopedia of Drug Metabolism and Interactions, vol. 3. John Wiley & Sons, Inc., 2012, chap. 8. DOI: 10.1002/9780470921920.edm028.
45. J. K. Wickliffe, L. A. Galbert, M. M. Ammenheuser, S. M. Herring, J. Xie, O. E. Masters, E. C. Friedberg, R. S. Lloyd, J. B. Ward,. 3,4-Epoxy-1-butene, a reactive metabolite of 1,3-butadiene, induces somatic mutations in Xpc-null mice. Environ. Mol. Mutagen. 2006, 47, 67.
46. S. Nakayama, H. Takakusa, A. Watanabe, Y. Miyaji, W. Suzuki, D. Sugiyama, K. Shiosakai, K. Honda, N. Okudaira, T. Izumi,. Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug Metab. Dispos. 2011, 39, 1247.
47. J. Uetrecht,. Idiosyncratic drug reactions: Current understanding. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 513.